HC Wainwright Has Lowered Expectations for Zura Bio (NASDAQ:ZURA) Stock Price

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Zura Bio (NASDAQ:ZURA - Free Report) had its price target trimmed by HC Wainwright from $3.00 to $2.00 in a research report released on Tuesday,Benzinga reports. The brokerage currently has a neutral rating on the stock. HC Wainwright also issued estimates for Zura Bio's FY2025 earnings at ($0.74) EPS.

Other equities analysts also recently issued research reports about the company. Oppenheimer dropped their price target on Zura Bio from $17.00 to $16.00 and set an "outperform" rating on the stock in a research report on Friday, August 15th. Chardan Capital reissued a "buy" rating and set a $10.00 price target on shares of Zura Bio in a research report on Friday, August 15th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $14.00.

Zura Bio Trading Up 1.0%

Shares of ZURA traded up $0.02 during midday trading on Tuesday, reaching $2.01. 585,013 shares of the stock were exchanged, compared to its average volume of 385,887. Zura Bio has a 52 week low of $0.97 and a 52 week high of $5.07. The company's 50 day moving average is $1.43 and its two-hundred day moving average is $1.32. The company has a market capitalization of $137.44 million, a P/E ratio of -2.87 and a beta of -0.06.

Zura Bio (NASDAQ:ZURA - Get Free Report) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.02. On average, sell-side analysts expect that Zura Bio will post -0.65 EPS for the current year.

Institutional Investors Weigh In On Zura Bio

A number of hedge funds have recently made changes to their positions in ZURA. Two Sigma Advisers LP purchased a new stake in Zura Bio in the fourth quarter valued at about $32,000. Savant Capital LLC raised its stake in Zura Bio by 190.4% in the second quarter. Savant Capital LLC now owns 32,409 shares of the company's stock valued at $34,000 after buying an additional 21,249 shares during the last quarter. ProShare Advisors LLC purchased a new stake in Zura Bio in the fourth quarter valued at about $35,000. XTX Topco Ltd purchased a new stake in Zura Bio in the fourth quarter valued at about $44,000. Finally, Wells Fargo & Company MN raised its stake in Zura Bio by 68.6% in the fourth quarter. Wells Fargo & Company MN now owns 23,053 shares of the company's stock valued at $58,000 after buying an additional 9,379 shares during the last quarter. 61.14% of the stock is currently owned by hedge funds and other institutional investors.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.